ARCHER 1050: Dacomitinib vs Gefitinib for Advanced EGFR Mutation Positive NSCLC - 102164

Spotlight
Video

ARCHER 1050: Dacomitinib vs Gefitinib for Advanced EGFR Mutation Positive NSCLC

Loading........
Description: H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract LBA9007: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
Shared By : AnnualMeeting2017
Posted on : 06/16/17
Added : 10 months ago